Medicine
Trogarzo 199.5 mg/1.33 mL injection
Trogarzo 199.5 mg/1.33 mL injection is a prescription medicine containing Ibalizumab for intravenous use, marketed by Theratechnologies, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store vials under refrigeration at 2 to 8ºC (36-46 ºF). Do not freeze and…
Key facts
- Active ingredient (INN)
- Ibalizumab
- Brand
- Trogarzo
- Strength
- 199.5 mg/1.33 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 2 vials of 1.33 mL
- Marketing authorisation holder
- Theratechnologies
- Manufacturer
- Theratechnologies
- Origin register
- US FDA, United States
- Storage
- Store vials under refrigeration at 2 to 8ºC (36-46 ºF). Do not freeze and protect from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AX23 Ibalizumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 April 2018
- Identifiers
- RxCUI 2043317, 2043322DailyMed set ID c548ad82-9d1f-4d16-95b6-4e6106badf43NDC 62064-122Application BLA761065
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 vial, single-use in 1 carton / 1.33 mL in 1 vial, single-use | 62064-122-02 | Theratechnologies | 20 April 2018 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Ibalizumab is a CD4-directed blocking antibody indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen. MedsAcross supplies Ibalizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about IbalizumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- TROGARZO prescribing information (Theratechnologies) · U.S. National Library of Medicine, DailyMed
Need Trogarzo 199.5 mg/1.33 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.